Prostate cancer patients who are prescribed oral erectile medication before and after radiation therapy have improved sexual function, according to a research team at Memorial Sloan Kettering Cancer Center.
New data reveals that women treated with radiation to the chest for childhood cancer have a high risk of developing breast cancer similar to that of women with BRCA1/2 mutations. The study, led by Memorial Sloan Kettering Cancer Center biostatistician Chaya Moskowitz, PhD, was presented today at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
Researchers from Memorial Sloan Kettering Cancer Center have begun testing for three new genetic targets and found that together they occur in approximately 50 percent of patients with squamous cell carcinomas of the lung, which affects 40,000 Americans each year. Initial findings of the research will be presented on June 4 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
Memorial Sloan Kettering Cancer Center’s website has been nominated for The Webby Award, the most prestigious international award honoring excellence on the Internet. Selected from among nearly 10,000 total entries, the Center’s website is one of five nominated in the Health category.
A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.
Memorial Sloan Kettering and IBM have agreed to collaborate on the development of a powerful tool built upon IBM Watson to provide medical professionals with improved access to comprehensive cancer data and practices.
Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan Kettering Cancer Center, will be published in the March 22 issue of the New England Journal of Medicine.
A rarely seen phenomenon in cancer patients — in which focused radiation to the site of one tumor is associated with the disappearance of metastatic tumors all over the body — has been reported in a patient with melanoma treated with the immunotherapeutic agent ipilimumab (Yervoy™).